Nice does not recommend Eli Lilly’s lung cancer drug in draft guidance
The National Institute of Care and Excellence (Nice) did not recommend US drugmaker Eli Lilly’s (NYSE: LLY) Portrazza to treat lung cancer saying the therapy cost too much compared to combination chemotherapy.
The appraisal committee also concluded that necitumumab did not meet the criteria to be considered for use in the Cancer Drugs Fund as it was not cost-effective and no clinical uncertainties could be addressed from further data collection.
The regulator in a draft guidance however, acknowledged that necitumumab provides small improvements in overall survival.
Bristol Myers Squibb has announced that the US Food and Drug Administration (FDA) has approved …
Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Zepbound …